Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

VUMC receives $11 million renewal grant to advance pulmonary fibrosis research

New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

Scientists use Regeneration Intelligence to assess perturbation status of many signaling pathways

Scientists use Regeneration Intelligence to assess perturbation status of many signaling pathways

Advances in inhaled drug delivery: an interview with Dr Robert Clarke

Advances in inhaled drug delivery: an interview with Dr Robert Clarke

Wresting back control of CHI3L1 protein could stave off cancer spread in mice

Wresting back control of CHI3L1 protein could stave off cancer spread in mice

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

3-D imaging of fibroblastic foci may help researchers study disease progression in IPF patients

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

VolitionRx's NuQ blood test accurately detects 86% of subjects with Idiopathic Pulmonary Fibrosis

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis: an interview with Dr Kristin Highland

New international survey provides insights into emotional truths of living with IPF

New international survey provides insights into emotional truths of living with IPF

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

IPF-PRO Registry data sheds light on characteristics of people with idiopathic pulmonary fibrosis

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Boehringer Ingelheim, BioMed X apply crowdsourcing approach to establish research team for identifying COPD treatment

Ex-vivo lung perfusion technique can reduce risk of transplant rejection

Ex-vivo lung perfusion technique can reduce risk of transplant rejection

Simple stem cell production method shows promise in mice for treating IPF

Simple stem cell production method shows promise in mice for treating IPF

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases